It is anticipated that extreme weather events due to climate change will increase the prevalence of a number of acute and chronic diseases. As a result, the demand for drugs to prevent or treat those conditions is likely to increase.
Prescription Drugs
Reports
Displaying 1 - 10 of 87. 10 per page. Page 1.
Advanced SearchResearch Summary
FDA Breakthrough Therapy Designation Reduced Late-Stage Drug Development Time
This landing page presents the abstract of a paper published in Health Affairs. The full text of the article is available at: https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2023.00837.
ASPE Issue Brief
Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices
The Inflation Reduction Act (IRA) makes improvements to Medicare to increase accessibility and affordability of prescription drugs for Medicare enrollees, reduce the rate of growth in Medicare drug spending, and improve the financial sustainability of the Medicare program.
ASPE Data Point
Linking Medical Product Manufacturing Locations with Natural Hazard Risk: Implications for the Medical Product Supply Chain
This ASPE data point links manufacturer location data with the Federal Emergency Management Agency (FEMA) National Risk Index (NRI), which describes relative risk of experiencing a variety of natural hazards in order to highlight the ways in which natural disasters may pose supply chain vulnerabilities within the U.S.
ASPE Issue Brief
Medical Product Shortages in the United States: Demographic and Geographic Factors and Impacts
Medical product shortages are an ongoing public health concern, with at least 140 products in shortage as of July 2024.We use the Household Pulse Survey to examine how many adults are affected by shortages of critical medical products in the United States.In fall 2023, shortages of medical products impacted about 38.8 million (18 percent) of individuals in the United Stat
ASPE Issue Brief
Impacts of a Nonprofit Membership-Based Pharmaceutical Company on Volume of Drugs Sold and Drug Prices: A Case Study
We report findings of a case study of Civica Rx, a U.S. nonprofit pharmaceutical company whose model is based on long-term hospital membership agreements with minimum volume commitments and buffer stock requirements.Related Products:
Report
The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential Medicines and Low-Cost Medicines
We report findings of a study that described the emerging nonprofit pharmaceutical industry and its commercialization activities to enhance access to affordable and essential drugs, or resiliency in the supply chains of medical products.
Research Summary
Costs of Drug Development and Research and Development Intensity in the US, 2000-2018
This landing page represents the abstract of a paper published in JAMA. The full text of the article is available at: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820562.Abstract
ASPE Data Point
Inflation Reduction Act Research Series: Medicare Part D Enrollee Vaccine Use After Elimination of Cost Sharing for Recommended Vaccines in 2023
Effective January 1, 2023, the Inflation Reduction Act (IRA) eliminated cost sharing and deductibles for adult vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) covered under Medicare Part D. In 2023, 10.3 million Medicare Part D enrollees received a recommended vaccine free of charge, which saved enrollees more than $400 million in out-of-pocket costs.
Report
Impact of Drug Shortages on Patients in the United States: A Case Study of Three Drugs
Drug shortages are a persistent problem that can cause substantial disruption in patient treatment regimens and adversely impact a patient’s health. Drug shortages can have severe consequences for patients, including high costs, delayed care, and potential medication errors or unintended side effects when using alternative or unfamiliar drugs.